dc.contributor.author |
Glazer, Evan |
|
dc.contributor.author |
Tseng, Jennifer |
|
dc.contributor.author |
Al-Refaie, Waddah |
|
dc.contributor.author |
Solorzano, Carmen |
|
dc.contributor.author |
Liu, Ping |
|
dc.contributor.author |
Willborn, Katherine |
|
dc.contributor.author |
Abdalla, Eddie |
|
dc.contributor.author |
Vauthey, Jean-Nicolas |
|
dc.date.accessioned |
2015-11-19T08:09:23Z |
|
dc.date.available |
2015-11-19T08:09:23Z |
|
dc.date.copyright |
2010 |
|
dc.date.issued |
2015-11-19 |
|
dc.identifier.issn |
1365-182X |
en_US |
dc.identifier.uri |
http://hdl.handle.net/10725/2615 |
|
dc.description.abstract |
Background: Surgical cytoreduction and endocrine blockade are important options for care for neuroendocrine liver metastases. We investigated the long-term survival of patients surgically treated for hepatic neuroendocrine metastases.
Methods: Patients (n= 172) undergoing operations for neuroendocrine liver metastases from any primary were identified from a prospective liver database. Recorded data and medical record review were used to analyse the type of procedure, length of hospital stay, peri-operative morbidity, tumour recurrence, progression,and survival.
Results: The median age was 56.8 years (range 11.5–80.7 years). 48.3% of patients were female. Median overall survival was 9.6 years (range 89 days to 22 years). On multivariate analysis, lung/thymic primaries were associated with worse survival [hazard ratio (HR): 15.6, confidence interval (CI): 4.3–56.8, P= 0.002]. Severe post-operative complications were also associated with worse long-term survival (P < 0.001). A positive resection margin status (R1) was not associated with a worse overall survival probability (P∼ 0.8).
Discussion: Early and aggressive surgical management of hepatic metastases from neuroendocrine tumours is associated with significant long-term survival rates. Radiofrequency ablation is a reasonable option if a lesion is unresectable. R1 resections, unlike many other cancers, are not associated with a worse overall survival. |
en_US |
dc.language.iso |
en |
en_US |
dc.title |
Long-term survival after surgical management of neuroendocrine hepatic metastases |
en_US |
dc.type |
Article |
en_US |
dc.description.version |
Published |
en_US |
dc.author.school |
SOM |
en_US |
dc.author.idnumber |
201100945 |
en_US |
dc.author.woa |
N/A |
en_US |
dc.author.department |
N/A |
en_US |
dc.description.embargo |
N/A |
en_US |
dc.relation.journal |
HBP |
en_US |
dc.journal.volume |
12 |
en_US |
dc.journal.issue |
6 |
en_US |
dc.article.pages |
427-433 |
en_US |
dc.keywords |
Neuroendocrine |
en_US |
dc.keywords |
Carcinoid |
en_US |
dc.keywords |
Liver metastases |
en_US |
dc.keywords |
Liver resection |
en_US |
dc.keywords |
Radiofrequency ablation |
en_US |
dc.keywords |
Survival |
en_US |
dc.identifier.doi |
http://dx.doi.org/10.1111/j.1477-2574.2010.00198.x |
en_US |
dc.identifier.ctation |
Glazer, E. S., Tseng, J. F., Al‐Refaie, W., Solorzano, C. C., Liu, P., Willborn, K. A., ... & Curley, S. A. (2010). Long‐term survival after surgical management of neuroendocrine hepatic metastases. Hpb, 12(6), 427-433. |
en_US |
dc.author.email |
eddie.abdalla@lau.edu.lb |
|